

Circadian appoints Dr Errol Malta as non-executive director

The Board of Directors of Circadian Technologies Limited (“Circadian”) is pleased to announce that today Dr Errol Malta has been appointed as a non-executive Director of the company. Dr Malta has been the Chairman of the company’s Product Development Review Committee since its inception in 2008 and will continue in this role. Broadly speaking, the role of this committee of the board is to provide advice and scrutinise Circadian’s drug development and commercialisation strategies.

Dr Malta has more than 20 years experience in drug development within the pharmaceutical/biotechnology industry. During that period he worked with Amgen Inc for more than 10 years, eight of which were served at its global headquarters in California, USA, where he was Product Development Team Leader. In this role, he was responsible for global drug development and the commercialisation of a number of different protein molecules in the US, Europe and Japan. He was responsible for five successful new-molecule IND submissions to FDA and other regulatory agencies, subsequent phase I/II programs, and a number of phase III and IV trials.

Upon his return to Australia, Errol was appointed Director of Scientific Affairs at Amgen Australia and Head of the Melbourne office. Errol has previous director positions in the Australian biotechnology sector with Alchemia Ltd, Avexa Ltd, NeuProtect Pty Ltd, NexPep Pty Ltd, Promics Ltd and Cortical Pty Ltd. Errol has been a consultant to over 20 biotechnology companies in early phase product development in Australia and the USA. He is a PhD graduate of the University of Melbourne and a Fellow of the Australian Institute of Company Directors, and has successfully completed the UCLA (Anderson School) Executive Program in Management.

Dr Malta said “I am delighted to be increasing my involvement with Circadian by accepting the directorship at this exciting time in its history and look forward to working more closely with the Circadian Board and management.”

Circadian’s Chairman, Dominique Fisher said “Errol’s vast international drug development and commercialisation experience has thus far been a great asset to the Product Development Review Committee and his becoming a member of the Circadian Board further strengthens the nexus between this committee and the Board.”

Further information:

Dominique Fisher
Chairman
Phone: 61 3 9826 0399

Robert Klupacs
Managing Director
Phone: 61 3 9826 0399